Factors associated with HBV Virological Breakthrough

Abstract

Background

Little is known about non-adherence to HBV therapy. This study aimed to investigate the relationship between self-reported missed days of antiviral therapy and HBV virological breakthrough and factors associated with virological breakthrough.

Methods

A cross-sectional survey of 211 HBV patients receiving oral antiviral therapies was undertaken at three tertiary hospitals in Sydney, Australia. Associations between 0 to >6 missed days in the last 30 days and virological breakthrough (defined as >10-fold rise in serum HBV DNA above nadir or after achieving virological response in the last 12 months) were examined. Logistic regression analyses determined the number of missed days most strongly associated with virological breakthrough and the associated factors. We report odds ratios (ORs) and relative risks (RRs).

Results

Of the 204, 32 participants (15.6%) had quantifiable HBV DNA levels (>20 IU/ml); 15 (46.8%) of them experienced virological breakthrough. Participants reported never missing medication (n=130, 63.7%) or missing 1 day (n=23, 11.3%), >1 day (n=23, 11.3%), 2–6 days (n=15, 7.3%) and >6 days (n=13, 6.4%). The most discriminating definition of non-adherence was missing >1 day of medication (RR=8.3; OR=10.2, 95% CI 3.1, 33.8, receiver operating characteristic curve 0.76). Factors independently associated with virological breakthrough included non-adherence (OR=9.0, 95% CI 2.5, 31.9) diagnosed with HBV ≤14 years (OR=5.3, 95% CI 1.0, 26.2) and age ≤47 years (OR=5.4, 95% CI 1.1, 26.9).

Conclusions

Results provide an evidence-based definition of non-adherence to inform clinical practice and provide a basis for key patient education messages. Closer monitoring of groups at risk of viral breakthrough is required.

References

Lavanchy

Chronic viral hepatitis as a public health issue in the world.

Best Pract Res Clin Gastroenterol 2008; 22: 991–1008.

Lavanchy

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.

J Viral Hepat 2004; 11: 97–107.

The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia annual surveillance report 2015. Sydney, Australia: The Kirby Institute, UNSW Australia 2015. (Accessed 1 February 2016.) Available from http://kirby.unsw.edu.au/surveillance/2015-annual-surveillance-report-hiv-viral-hepatitis-stis.

Walter

S.R.

, Thein

H.H.

, Amin

Trends in mortality after diagnosis of hepatitis B or C infection: 1992–2006.

J Hepatol 2011; 54: 879–886.

Fattovich

, Stroffolini

, Zagni

, Donato

Hepatocellular carcinoma in cirrhosis: incidence and risk factors.

Gastroenterology 2004; 127 Suppl 1: S35–S50.

Liaw

Y.F.

Chronic hepatitis B virus infection: spectrum, pathogenesis and natural history. In: Sarin

S.K.

, Okudo

(editors). Hepatitis B and C. New Delhi: Harcourt; 2002.

Fattovich

, Bortolotti

, Donato

Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors.

J Hepatol 2008; 48: 335–352.

Lok

A.S.F.

Hepatitis B. In: Dooley

, Lok

, Burroughs

, Heathcote

(editors). Sherlock's Diseases of the Liver and Biliary System. UK: Blackwell Publishing; 2011. p. 367–392.

Iloeje

U.H.

, Yang

H.I.

, Chen

C.J.

Natural history of chronic hepatitis B: what exactly has REVEAL revealed?

Liver Int 2012; 32: 1333–1341.

10.

Suzuki

, Suzuki

, Kawamura

Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?

J Gastroenterol Hepatol 2009; 24: 429–435.

11.

Hongthanakorn

, Chotiyaputta

, Oberhelman

Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.

Hepatology 2011; 53: 1854–1863.

12.

Fung

, Lai

C.L.

, Seto

W.K.

, Yuen

M F.

Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B.

J Antimicrob Chemother 2011; 66: 2715–2725.

13.

Wang

, Wang

, Huang

Acute liver failure resulting from discontinuation of nucleoside analogues in chronic hepatitis B patients: a report of two cases.

Scand J Infect Dis 2013; 45: 158–160.

14.

Lok

, McMahon

AASLD Practice Guideline Update: Chronic hepatitis B.

Hepatology 2009; 50: 661–662.

15.

European Association for the Study of the Liver.

EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection.

J Hepatol 2012; 57: 167–185.

16.

Gastroenterology Society of Australia. Australia and New Zealand Chronic HBV recommendations. Mulgrave, Victoria: Digestive Health Foundation, 2009/2010.

17.

Liaw

Y.F.

, Kao

J-H

, Piratvisuth

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.

Hepatol Int 2012; 6: 535–561.

18.

Kamezaki

, Kanda

, Wu

Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication.

Scand J Gastroenterol 2011; 46: 1111–1117.

19.

Pol

, Lampertico

First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice.

J Viral Hepat 2012; 19: 377–386.

20.

Chotiyaputta

, Hongthanakorn

, Oberhelman

Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs.

J Viral Hepat 2012; 19: 205–212.

21.

Batirel

, Guclu

, Arslan

Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naive patients with chronic hepatitis B: a multicenter real-life study.

Int J Infect Dis 2014; 28: 153–159.

22.

Hilleret

, Larrat

, Stanke-Labesque

, Leroy

Does adherence to hepatitis B antiviral treatment correlate with virological response and risk of breakthrough?

J Hepat 2011; 55: 1468–1469.

23.

Kitrinos

K.M.

, Corsa

, Liu

No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B.

Hepatology 2014; 59: 434–442.

24.

Kamezaki

, Kanda

, Arai

Adherence to medication is a more important contributor to viral breakthrough in chronic hepatitis B patients treated with entecavir than in those with lamivudine.

Int J Med Sci 2013; 10: 567–574.

25.

Polis

, Zablotska-Manos

, Zekry

, Maher

Adherence to hepatitis B anti-viral therapy: a qualitative study.

Gastroenterol Nurs; in press.

26.

Metz

C.E.

Basic principles of ROC analysis.

Semin Nucl Med 1978; 8: 283–298.

27.

O'Sullivan

B.G.

, Gidding

H.F.

, Law

Estimates of chronic hepatitis B virus infection in Australia, 2000.

Aust N Z J Public Health 2004; 28: 212–216.

28.

Nguyen

V.T.T.

, Razali

, Amin

, Law

M.G.

, Dore

G.J.

Estimates and projections of hepatitis B-related hepatocellular carcinoma in Australia among people born in Asia–Pacific countries.

J Gastroenterol Hepatol 2008; 23: 922–929.

29.

MacLachlan

J.H.

, Allard

, Towell

, Cowie

B.C.

The burden of chronic hepatitis B virus infection in Australia, 2011.

Aust N Z J Public Health 2013; 37: 416–422.

30.

Cowie

The linguistic demography of Australians living with chronic hepatitis B.

Aust N Z J Public Health 2011; 35: 12–15.

31.

Yapali

, Talaat

, Lok

A.S.

Management of hepatitis B: our practice and how it relates to the guidelines.

Clin Gastroenterol Hepatol 2014; 12: 16–26.

32.

Schweitzer

, Horn

, Mikolajczyk

R.T.

, Krause

, Ott

J.J.

Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013.

Lancet 2015; 386: 1546–1555.

33.

Howell

, Van Gemert

, Lemoine

, Thursz

, Hellard

An overview of hepatitis B prevalence, prevention, and management in the Pacific Islands and Territories.

J Gastroenterol Hepatol 2014; 29: 1854–1866.

34.

Marcellin

, Heathcote

E.J.

, Buti

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

N Engl J Med 2008; 359: 2442–2455.

35.

Yuen

M.F.

, Lai

C.L.

Treatment of chronic hepatitis B: evolution over two decades.

J Gastroenterol Hepatol 2011; 26 Suppl 1: 138–143.

36.

Chang

T.T.

, Lai

C.L.

, Kew Yoon

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

Hepatology 2010; 51: 422–430.

37.

Heathcote

E.J.

, Marcellin

, Buti

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

Gastroenterology 2011; 140: 132–143.

38.

van Vlerken

L.G.

, Arends

, Lieveld

F.I.

Real life adherence of chronic hepatitis B patients to entecavir treatment.

Dig Liver Dis 2015; 47: 577–583.

39.

Chotiyaputta

, Peterson

, Ditah

, Goodwin

, Lok

Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B.

J Hepatol 2011; 54: 12–18.

40.

Giang

, Selinger

C.P.

, Lee

A.U.

Evaluation of adherence to oral anti-viral hepatitis B treatment using structured questionnaires.

World J Hepatol 2012; 4: 43–49.

41.

Sogni

, Carrieri

M.P.

, Fontaine

The role of adherence in virological suppression in patients receiving anti-HBV analogues.

Antivir Ther 2012; 17: 395–400.

42.

Lieveld

F.I.

, Van vlerken

L.G.

, Siersema

P.D.

, Erpecum

K.J.

Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review.

Ann Hepatol 2013; 12: 380–391.

43.

Lee

Adherence with use of oral agents in the treatment of chronic hepatitis B.

Curr Hepatol Rep 2012; 11: 70–74.

44.

Lim

Y.S.

, Byun

K.S.

, Yoo

B.C.

Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.

Gut 2016; 65: 852–860.